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Background: Connexin proteins are essential for 
cell differentiation, function and survival. 
Results: Global deletion of Cx37 results in 
increased bone mass due to reduced osteoclast 
maturation. 
Conclusion: Our findings demonstrate a 
previously unrecognized role of Cx37 in bone 
homeostasis in vivo 
Significance: Therapeutic approaches to increase 
bone mass might be developed by interfering with 
Cx37 function. 
ABSTRACT 
Connexin (Cx) proteins are essential for cell 
differentiation, function and survival in all 
tissues with Cx43 being the most studied in 
bone. We now report that Cx37, another 
member of the connexin family of proteins, is 
expressed in osteoclasts, osteoblasts and 
osteocytes. Mice with global deletion of Cx37 
(Cx37-/-) exhibit higher BMD, cancellous bone 
volume, and mechanical strength compared to 
wild type littermates. Osteoclast number and 
surface are significantly lower in bone of Cx37-/- 
mice. In contrast, osteoblast number and 
surface and bone formation rate in bones from 
Cx37-/- mice are unchanged.  Moreover, 
markers of osteoblast activity ex vivo and in 
vivo are similar to those of Cx37+/+ littermates. 
sRANKL/M-CSF treatment of non-adherent 
Cx37-/- bone marrow cells rendered a 5-fold 
lower level of osteoclast differentiation 
compared to Cx37+/+ cell cultures. Further, 
Cx37-/- osteoclasts are smaller and have fewer 
nuclei per cell. Expression of RANK, TRAP, 
cathepsin K, calcitonin receptor, MMP9, 
NFATc1, DCSTAMP, ATP6v0d1 and CD44, 
markers of osteoclast number, fusion or 
activity, is lower in Cx37-/- osteoclasts compared 
to controls. In addition, non-adherent bone 
marrow cells from Cx37-/- mice exhibit higher 
levels of markers for osteoclast precursors, 
suggesting altered osteoclast differentiation. 
The reduction of osteoclast differentiation is 
associated with activation of Notch signaling. 
We conclude that Cx37 is required for 
osteoclast differentiation and fusion and its 
absence leads to arrested osteoclast maturation 
and high bone mass in mice. These findings 
demonstrate a previously unrecognized role of 
Cx37 in bone homeostasis that is not 
compensated for by Cx43 in vivo. 
Connexins (Cx1) are transmembrane proteins 
expressed in osteoblasts, osteocytes, and 
osteoclasts (1). Six connexin proteins arrange in 
the cell membrane to form hemichannels or 
connexons. Connexins mediate intercellular 
communication through gap junction channels 
formed by two connexons that connect adjacent 
cells or as unopposed hemichannels, via the 
release of small molecules to the extracellular 
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medium (2). The C-terminus of connexin proteins 
faces the cytoplasm and through interactions with 
kinases and structural molecules participate in the 
regulation of intracellular signaling independently 
of channel activity (3).   
Most cells express multiple connexins that form 
hemichannels composed of one or two different 
connexins (4). Cx43, for example, can form 
hemichannels with Cx37, Cx40 or Cx46. In 
addition, hemichannels composed by one connexin 
protein in one cell can dock with hemichannels 
formed by another connexin in a neighboring cell 
to form heterotypic gap junction channels, which 
exhibit unique properties, different from channels 
composed by only one connexin (5).  
In bone, Cx43 is the main connexin expressed 
in osteoblasts, osteocytes and osteoclasts, and it 
has been the focus of research on the role of this 
family of proteins in the skeleton (1). A recent 
gene array study showed that Cx37 (GJA4) is also 
expressed in bone cells, and it is 5 times more 
abundant in osteocytes than in osteoblasts (6). 
However, Cx37 expression in osteoclasts and their 
precursors has not been examined. In addition, the 
relative expression level of Cx37 compared to 
Cx43 in bone, and the role of Cx37 on bone cell 
function remain unknown. 
Cx37 is expressed in monocytes/macrophages, 
platelets, kidney and ovaries, but it is more 
abundant in endothelial cells in the blood vessels 
(7-9). However, Cx37 deletion does not impair 
vascular function because Cx40, which is also 
expressed in endothelial cells, can compensate for 
the absence of Cx37  (10;11). Indeed, double 
knockout mice lacking both Cx37 and Cx40 die at 
birth as result of vascular abnormalities. The main 
phenotypic characteristic of Cx37 null mice is 
female sterility due to lack of terminal oocyte 
maturation, absence of ovulation, and 
accumulation of abnormal corpora lutea. In 
contrast, male homozygous Cx37-/- and 
heterozygous Cx37+/- mice breed normally.  
Variants of the Cx37 gene are associated with 
several human diseases. Thus, a Cx37 gene 
polymorphism resulting from replacement of 
serine 319 (319S) by proline (319P) in the 
regulatory cytoplasmic tail is a diagnostic marker 
for atherosclerosis in humans; with higher risk for 
myocardial infarction and reduced risk of coronary 
artery disease in patients carrying the Cx37-319S 
allele. The increased permeability exhibited by 
Cx37-319P hemichannels may mediate the 
differential effects of the two Cx37 polymorphic 
alleles. In addition, Cx37-319P, but not Cx37-
319S, decreases proliferation when transfected 
into HeLa or SK-HEP-1 cells (12). The proline 
variant can be phosphorylated by GSK3β, an event 
that leads to reduced channel activity and 
decreased proliferation in HeLa cells. 
Interestingly, the same human gene polymorphism 
is associated with bone mass in a Japanese 
population, with men carrying the Cx37-319S 
allele exhibiting lower total body, lumbar spine, 
femoral neck, and trochanter  BMD (13).  
We examined in the current study the skeletal 
phenotype of mice with global deletion of Cx37. 
We found that Cx37 is expressed in osteoblasts, 
osteocytes and osteoclasts, albeit at lower levels 
than Cx43. Nevertheless, lack of Cx37 impairs 
osteoclastogenesis, without affecting osteoblast 
differentiation or function. Our data indicates that 
reduced bone resorption in Cx37 null mice leads to 
increased bone mass and bone volume, in 
particular in cancellous bone of the vertebrae.  
EXPERIMENTAL PROCEDURES 
Animals–Mice with global deletion of Cx37, 
generated by A. Simon (14) and provided by J.M. 
Burt (University of Arizona, Tucson, AZ), were 
maintained in a C57BL/6 background. Mice 
expressing green fluorescent protein under the 
control of the dentin matrix protein 1 promoter 
(DMP1-GFP) in a C57BL/6 background were 
previously described (15). All mice were fed a 
regular diet and water ad libitum and maintained 
on a 12h light/dark cycle. All protocols involving 
mice were approved by the Institutional Animal 
Care and Use Committee of Indiana University 
School of Medicine.  
Mice were genotyped by PCR using specific 
primer sets as follows: wild type allele was 
detected using 5’-TGC TAG ACC AGG TCC 
AGG AAC-3’ and 5’-GTC CCT TCG TGC CTT 
TAT CTC-3’; and the mutant allele detected by 5’-
GAT CTC TCG TGG GAT CAT TG-3’ and 5’-
TGC TAG ACC AGG TCC AGG AAC-3’. An 
amplified fragment of 750bp corresponds to the 
wild type allele and of 233bp to the mutant allele.  
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Mice received intraperitoneal injections of 
calcein (20 mg/kg, Sigma Chemical, St. Louis, 
MO, USA) and alizarin red (20 mg/kg, Sigma) 7 
and 2 days before sacrifice, respectively, to allow 
for dynamic histomorphometric measurements 
(16).  
Cell preparations and culture–OB-6 osteoblastic 
cells and MLO-Y4 cells were cultured as 
previously published (17;18). Immortalized mouse 
calvaria osteoblastic (MOB) cells were provided 
by M. M. Thi (Albert Einstein School of 
Medicine) and cultured in α-MEM containing 10% 
FBS and 1% penicillin-streptomycin (19). Calvaria 
cells were isolated from DMP1-8kb-GFP 
transgenic mice. GFP-expressing cells (osteocyte-
enriched) were separated from GFP-negative cells 
(osteoblast-enriched) by sorting the cell 
suspension using a FACSAria flow cytometer (BD 
Biosciences, Sparks, MD) at the Indiana 
University Flow Cytometry Core Facility, as 
published (20).  
Bone marrow cells were isolated from Cx37+/+ 
and Cx37-/- by flushing the bone marrow out with 
α-MEM supplemented with 15% FBS and 1% 
penicillin/streptomycin and then plated at a density 
of 4x105/cm in 24-well plates for 48h. Non-
adherent cells were collected and either plated for 
osteoclast formation or digested to obtain mRNA. 
For the osteoclastogenesis assay, 2x105 non-
adherent cells/cm2 were seeded and cultured with 
20 ng/ml recombinant murine M-CSF (PeproTech 
Inc., Rocky Hill, NJ, USA) for 24h. Subsequently, 
80 ng/ml recombinant murine sRANKL 
(PeproTech Inc., Rocky Hill, NJ, USA) was 
added. Medium was changed every two days for 5 
days. Osteoclasts were enumerated after staining 
for TRAPase using a commercial kit (Sigma-
Aldrich Inc., St. Louis, MO, USA.). Images were 
acquired using a Zeiss Axiovert 35 microscope 
equipped with a digital camera. mRNA was 
isolated from parallel cultures and gene expression 
was measured by quantitative RT-PCR (Applied 
Biosystems, Foster City, CA).  
The number of viable cells was assessed using 
the MTT assay in cells treated with 30 ng/ml M-
CSF for 24h, as previously described (20;21). 
Cells were pretreated for 1h with vehicle or 2 μM 
Notch signaling inhibitor GSI XX (Calbiochem, 
Gibbstown, NJ) (22). 
Adherent cells were collected after the initial 
48h in culture, plated at a density of 4x105/cm2 
and cultured until reaching 95-100% of 
confluence. Then, differentiation medium (α-
MEM supplemented with 10% FBS, 50µg/ml 
ascorbic acid and 10mM β-glycerophosphate) was 
added. Medium was changed every third day. 
After 14 days in culture cells were stained with 
Alizarin red for 10 min, as published (23). Images 
were acquired using a Zeiss Axiovert 35 
microscope equipped with a digital camera. After 
imaging the cells, Alizarin red was dissolved in 
10% acetic acid for 30 min at room temperature. 
The content of the wells were transferred to 
microtubes and incubated at 85°C for 10 min, 
followed by centrifugation and neutralization of 
the supernatants with 10% ammonium hydroxide. 
Absorbance at 405 nm was measured to estimate 
the level of mineralization. Parallel cultures were 
digested to obtain mRNA and perform quantitative 
RT-PCR (Applied Biosystems, Foster City, CA).  
Fluorescent-activated cell sorter (FACS)–Freshly 
isolated bone marrow cells were incubated with 
anti–Mac-1-APC (CD11b), and anti-
Gr1(granulocyte differentiation antigen 1)-FITC  
followed by sorting by FACS, as published (24). 
All antibodies were purchased from e-Biosciences. 
FACSCalibur and FlowJo were used for 
acquisition and analysis, respectively. 
Whole-mount skeletal staining–Cartilage and 
mineralized tissue were analyzed in newborn mice 
using alizarin red/alcian blue staining, as 
previously published (25). In brief, newborn mice 
were de-skinned, eviscerated, and kept in 100% 
ethanol for 48 h. The carcasses were fixed in 
acetone for 24 h and then stained for 5 days in a 
solution containing 0.1% alizarin red, 0.3% alcian 
blue, acetic acid, and 70% ethanol (1:1:1:17, 
vol/vol/vol/vol). Carcasses were then transferred 
to a solution of 1% KOH overnight, transferred to 
a solution of glycerol:KOH (2:8) overnight, and 
finally to 100% glycerol.  
Bone mineral density (BMD) and micro-computed 
tomography (μCT) analysis–Longitudinal study 
was performed monthly from 2 to 5 months of age 
by DEXA using a PIXImus densitometer (G.E. 
Medical Systems, Lunar Division, Madison, WI) 
(20). BMD measurements included total BMD 
 at B
IR
EM
E and U
N
IFESP on February 21, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
4 
 
(excluding the head and tail), L1-L6 vertebra 
(spinal BMD), and entire femur (femoral BMD). 
For μCT analysis, femora and lumbar vertebrae 
obtained from male  mice at age 2.5 and 5-month 
were cleaned of adhering tissue and frozen until 
imaging at 6 μm pixel resolution on a Skyscan 
1172 (SkyScan, Kontich, Belgium) (20).  
RNA extraction and quantitative RT-PCR (qPCR) 
–RNA was purified from cells or bones using 
Trizol reagent (Invitrogen), as previously 
described (26). qPCR was performed using the 
house-keeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), and the ∆Ct method. 
Primers and probes were designed using the Assay 
Design Center (Roche Applied Science, 
Indianapolis, IN) or were commercially available 
(Applied Biosystems, Foster City, CA).  
Bone histomorphometry–Vertebrae (L6 and L2 for 
2.5- and 5-month-old mice, respectively) were 
dissected, fixed, and embedded in methyl 
methacrylate. Static historphometric analysis was 
performed on TRAP stained-sections, as 
previously described (20). Sequential sections 
were stained with von Kossa tetrachrome to 
visualize mineralized bone (16). Dynamic 
histomorphometric analysis of bone sections was 
performed on unstained sections, avoiding the 
primary spongiosa. All measurements were 
obtained using OsteoMeasure high resolution 
digital video system (OsteoMetrics Inc., Decatur, 
GA). The terminology and units used are those 
recommended by the Histomorphometry 
Nomenclature Committee of the American Society 
for Bone and Mineral Research (27). 
Biomechanical testing–Femora and lumbar (L5) 
vertebrae obtained from 5-month-old mice were 
tested via three-point bending and compression, 
respectively, following previously published 
protocols with modifications (28). Briefly, bones 
were thawed to room temperature, hydrated in 
0.9% saline, and loaded to failure at 2 mm/min 
with force versus displacement data collected at 10 
Hz using a servo-hydraulic test system (Test 
Resources). Femora were loaded to failure in an 
anterior-posterior direction with the upper contact 
area at the mid-diaphysis (50% total bone length) 
and the bottom contact points centered around this 
point and separated by 8 mm. The posterior 
processes and end plates were removed prior to 
testing of the vertebra. Structural mechanical 
properties, ultimate load, stiffness, and energy to 
failure were determined from the load-deformation 
curves using standard definitions while material-
level estimations of ultimate stress, modulus, and 
toughness were calculated using standard 
equations. Cross-sectional moment of inertia and 
anterior-posterior diameter were determined by 
μCT and were used to calculate material-level 
properties, as previously described (29). 
Bone turnover markers–Plasma C-telopeptide 
fragments (CTX) (RatLaps, Immunodiagnostic 
Systems Inc., Fountain Hill, AZ, USA), 
osteocalcin (OCN) (Biomedical Technologies, 
Soughton, MA, USA) and sclerostin levels 
(ALPCO Immunoassays, Salem, NH, USA) were 
measured as described by the manufacturer. 
Alkaline phosphatase activity was assessed by a 
standard automated method using a Randox 
Daytona chemical analyser (Northern Ireland, 
United Kingdom). 
Histological visualization of ovaries–Ovaries were 
fixed in 3.7% PBS-buffered formaldehyde at room 
temperature for 48h, followed by transfer to 70% 
ethanol. Specimens were subsequently dehydrated 
in ascending ethanol concentrations and embedded 
in paraffin. 5μm-thick sections were processed for 
hematoxilin and eosin staining. Images were 
acquired using an Olympus BX51 TRF 
microscope equipped with a digital camera. 
Statistical analysis–Data were analyzed by using 
SigmaPlot (Systat Software Inc., San Jose, CA). 
Differences were evaluated by Student’s t-test and 
considered significant for p<0.05. All values are 
reported as the mean ± standard deviation (SD).  
 
RESULTS 
Cx37 is expressed in osteoblasts, osteocytes, and 
osteoclasts–Gene expression analysis shows that 
Cx37 is expressed in whole bone at about 4-times 
lower levels than Cx43 (Fig. 1a). Cx37 can also be 
detected at much lower levels than Cx43 in the 
OB-6 osteoblastic cells, in immortalized 
osteoblastic calvaria cells, and in MLO-Y4 
osteocytic cells. In primary osteoblasts, the 
expression of Cx37 is approximately 300-times 
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lower than that of Cx43, whereas in primary 
osteocytes it is approximately 60-times lower (Fig. 
1b). In addition, Cx37 is detected in osteoclasts 
generated by treatment of non-adherent bone 
marrow cells with M-CSF and sRANKL. In these 
osteoclast cultures the expression of Cx37 is also 
lower than Cx43 (approximately 120-fold).  
Global deletion of Cx37 in mice leads to high bone 
mass–Cx37 deficient mice did not exhibit gross 
abnormalities at birth, and qualitatively appear to 
have a distribution of cartilage and mineralized 
bone similar to that of wild type littermates (Fig. 
2a). Body weight was similar in male mice from 
either genotype from 2 to 5 month (Fig. 2b). 
Femoral length was not different between 
phenotypes at 5 months of age (15.19 ± 0.27 
versus 15.44 ± 0.18 mm for wild type Cx37+/+ and 
Cx37-/- mice, respectively). Female mice exhibit a 
slight increase in weight at 1 (not shown), 2 and 5 
months of age (Fig. 2b).  
Male Cx37-/- mice exhibit higher total (5-9%), 
spinal (11-21%) and femoral (8-21%) BMD 
compared to wild type littermates at each age 
examined (Fig. 2c). Female Cx37 deficient mice 
also exhibit higher bone mass, albeit less than 
males, with a 3-4% increase in total BMD and a 5-
7% increase in femoral BMD at 4 and 5 month of 
age.  
Cx37-/- mice exhibit increased cancellous bone 
volume and increased mechanical strength in the 
femur–μCT analysis showed higher bone volume 
and trabecular number in the cancellous bone of 
the lumbar vertebra at 2.5 and 5 months of age 
(Fig. 3a). This was associated with increased 
trabecular thickness and a tendency towards higher 
trabecular number in the young animals. In the 
older mice, only trabecular number was higher. 
Similar effects of Cx37 deletion were observed in 
the cancellous bone in the distal femur at 2.5 
months of age (Fig. 3b). However, there were no 
differences between genotypes in 5-month-old 
mice. Deletion of Cx37 does not result in major 
changes in cortical architecture or bone material 
density in the femoral midshaft compared to wild 
type littermates, with only a slight but significant 
reduction in cortical thickness (Fig. 3c). 
Lumbar vertebrae from Cx37 null mice 
exhibited higher energy to ultimate load, an 
indication of the capacity of the bone to resist 
compression forces (Fig. 4a). Ultimate force and 
stiffness showed a tendency towards higher values 
in mice lacking Cx37, but the difference did not 
reach significance.  Deletion of Cx37 resulted in 
higher cortical bone strength as evidenced by 
increased ultimate force and mechanical stiffness, 
compared to wild type littermates in the cortical 
bone of the femoral midshaft (Fig. 4b). 
Estimations of material properties, on the other 
hand, showed no difference between genotypes. 
Static histomorphometry revealed lower 
number of osteoclasts per bone surface (NOc/BS), 
and reduced bone surface covered by osteoclasts 
(OcS/BS) and eroded surface (ES/BS) on the 
vertebral cancellous surface of Cx37-/- mice 
compared to controls at 2.5 and 5 months of age 
(Fig. 5a and b). The number of osteoblasts 
(NOb/BS) and the bone surface covered by 
osteoblasts (ObS/BS), on the other hand, was not 
different between genotypes at either age. The 
lower osteoclast parameters combined with the 
lack of change on osteoblasts resulted in an 
increase in quiescent bone surface (QS/BS) in 
Cx37-/- mice. Dynamic histomorphometry showed 
no differences in MS/BS, MAR and BFR/BS, 
parameters which reflect osteoblast number and 
activity in 5-month-old mice (Fig. 5c). 
Differences in circulating markers of bone 
resorption (CTX) or formation, (osteocalcin and 
alkaline phosphatase), or in sclerostin, the 
inhibitor of Wnt signaling, were not detected in 
either male or female mice at 2, 3 or 5 months of 
age (Fig. 6).  
Deletion of Cx37 decreases osteoclast fusion and 
differentiation, but does not affect osteoblast 
differentiation or function–To test the cellular 
basis for the increased bone mass in the absence of 
Cx37, we examined osteoclast-specific gene 
expression in whole bone preparations. As 
expected, Cx37 expression was undetectable in 
lumbar vertebrae from Cx37-/- mice, while Cx43 
expression was not different from Cx37+/+ mice 
(Fig. 7a). Although the means of the osteoclast-
specific genes TRAP and cathepsin K were 
approximately half in Cx37-/- bones compared to 
Cx37+/+, the difference did not reach significance. 
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The ability of Cx37-deficient osteoclast precursors 
to generate mature cells ex vivo in the presence of 
M-CSF and sRANKL was impaired, as evidenced 
by a lower osteoclast number and size, and 
number of nuclei/osteoclast (Fig. 7b).  
Although, the percentage of CD11b-positive 
cells (expressing or not the myeloid cell marker 
Gr1) present in the bone marrow of Cx37-/- mice 
was similar to Cx37+/+ mice, as evidenced by 
FACS, non-adherent bone marrow cell 
preparations isolated from Cx37-/- mice exhibited 
higher expression of osteoclast precursors markers 
CD11b, CD14 and RANK, compared to cells 
isolated from wild type littermates (Fig. 7c). These 
findings suggest that in the absence of Cx37 the 
expression of osteoclast progenitor-associated 
genes is increased without a concomitant increase 
in the abundance of osteoclast precursor cells. 
Mature osteoclasts derived from wild type or 
Cx37-/- mice expressed similar levels of Cx43 
mRNA, but expressed reduced levels of 
osteoclast-specific genes (Fig. 7d). Thus, lack of 
Cx37 led to a reduction in RANK levels of 
approximately 30%, whereas the markers of 
mature osteoclasts TRAP, cathepsin K and 
calcitonin receptor were all approximately 50% 
lower. Moreover, NFATc1, a transcription factor 
essential for osteoclast differentiation induced by 
RANKL (30), was also lower in Cx37-deficient 
osteoclasts. Similarly, the expression of dendritic 
cell-specific transmembrane protein (DC-STAMP) 
and the d2 isoform of vacuolar ATPase Vo domain 
(Atp6v0d2), NFATc1 targets that participate in 
osteoclast fusion, were also reduced. MMP9 and 
CD44, which are involved in osteoclast migration 
and fusion (31-33), were also decreased in Cx37 
deficient cultures. On the other hand, other 
molecules associated with osteoclast function were 
either not changed (osteoclast-associated receptor, 
OSCAR) or their decrease did not reach 
significance (integrin β3 and E-cadherin). 
Recent evidence indicates that the Notch 
signaling pathway negatively modulates osteoclast 
differentiation (34;35). We therefore, investigated 
whether deleting Cx37 altered regulation of Notch 
signaling. Freshly isolated Cx37-deficient non-
adherent bone marrow cells expressed higher 
levels of the Notch1-3 receptors compared to wild 
type cells, whereas the expression of the Notch 
target gene Hey-1 was unchanged (Fig. 8a). 
Moreover, the number of viable cells in cultures 
treated with M-CSF for 24h was significantly 
higher in Cx37-/- cells, and this difference 
disappeared when the cultures were treated with a 
Notch inhibitor (Fig. 8b). Increased expression of 
the Notch target Hey-1 was detected in mature 
osteoclasts and in whole bone lysates, whereas the 
levels of the receptors Notch1-3 were either 
unchanged or slightly increased. This evidence 
suggests that elevation of Notch signaling pathway 
in the absence of Cx37 contributes to the 
inhibition of osteoclastogenesis in Cx37-/- mice. 
Ex vivo cultures of adherent bone marrow cells 
maintained in the presence of ascorbic acid and β-
glycerophophate to induce osteoblast 
differentiation showed no difference in calcium 
deposition, a marker for mineralizing activity, 
between cells isolated from Cx37-/- and Cx37+/+ 
controls (Fig. 9a). Moreover, the expression of the 
osteoblastic genes osteocalcin, alkaline 
phosphatase, collagen type 1a1, and bone 
sialoprotein was not affected by Cx37 deletion in 
the osteoblastic cells derived from adherent bone 
marrow cells (Fig. 9a) or in whole lumbar vertebra 
lysates (Fig. 9b). Similarly, no differences were 
seen in the level of mineralization on the vertebral 
bone in 2.5- and 5-month-old mice. 
 
DISCUSSION 
In this report, we describe the skeletal 
phenotype of mice with global deletion of Cx37, a 
member of the connexin family of proteins with 
previously unrecognized functions in bone cells. 
Cx37 is expressed in whole bone at levels about 4-
fold lower than Cx43. Osteoblasts, osteocytes and 
osteoclasts all express Cx37, albeit at 60-400 fold 
lower levels than Cx43. We found that the skeletal 
phenotype of mice with global deletion of the gene 
results from an osteoclast cell-autonomous defect. 
Although non-adherent bone marrow cells express 
higher levels of markers of osteoclast precursors, 
their ability to become mature osteoclasts is 
impaired.  This evidence, together with the 
decrease in osteoclast parameters in vivo, suggests 
that the increased bone mass and volume observed 
in Cx37-/- mice is due to defective osteoclast 
maturation and the consequent decreased 
osteoclast bone resorbing activity. Whether 
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decreased osteoclastogenesis in the absence of 
Cx37 is due to lack of cell-to-cell-communication, 
reduced communication with the extracellular 
medium through Cx37 hemichannels, or to 
defective Cx37-protein association independent of 
channel function, will be investigated in future 
studies.  
Similar to our in vivo results, treatment of 
osteoclast precursors with agents that disassemble 
connexin channels leads to decreased osteoclast 
differentiation in vitro, with reduced fusion of 
osteoclast precursors compared to vehicle treated 
cultures (36-38). GAP27, a peptide that inhibits 
the function of the channel/hemichannel formed 
by Cx43 or Cx37, has been shown to block 
osteoclast differentiation (39;40). This decrease in 
osteoclastogenesis was attributed to reduced Cx43 
function, since this was the only connexin protein 
described in osteoclastic cells. Our data, however, 
shows that Cx37 expression is required for 
osteoclast differentiation and the regulation of 
bone mass. A preliminary study presented in 
abstract form indicates that osteoclast-specific 
deletion of Cx43 has a similar impact on 
osteoclastogenesis as the absence of Cx37 (41). 
This raises the possibility that channels formed by 
both connexins (heteromeric) or docking of 
different channels each formed by one connexin 
are required for osteoclast maturation. The co-
localization of Cx43 and Cx37 in heteromeric 
channels may not only alter channel properties, but 
also affect the interaction of the connexins with 
intracellular signaling molecules. On the other 
hand, expression of Cx43, but not Cx37, in 
osteoblast precursors is required for full osteoblast 
differentiation and for normal ossification of the 
developing embryos (42), suggesting that in 
osteoblastic cells the two connexins do not 
interact, and that Cx43 is the main connexin active 
in these cells. 
Preliminary mechanistic studies show that 
cells lacking Cx37 exhibit increased Notch 
signaling activation in response to pro-
osteoclastogenic stimuli, whereas in mature 
osteoclasts, Notch1-3 mRNA levels were normal. 
Furthermore, the number of viable cells is higher 
in non-adherent bone marrow cells treated with M-
CSF, but returns to wild type control levels by 
inhibition of Notch signaling. The increase in cell 
number could be due to higher proliferation or 
reduced apoptosis. Enhanced proliferation of 
Cx37-/- osteoclast progenitor cells is supported by 
evidence showing that Cx37 suppresses the 
proliferation of rat insulinoma cells (43;44). Our 
data, however, contrast with evidence showing 
that deletion of Notch1-3 in osteoclast precursors 
using LysM-Cre (35), leads to an increase in 
proliferation. This discrepancy could be due to 
changes in other genes in the absence of Cx37, or 
to the temporal pre-osteoclast-specific elevation of 
Notch1-3 signaling in our studies. The expression 
of the Notch signaling target Hey-1 is highly 
increased in mature osteoclasts from Cx37-
deficient mice, consistent with evidence that the 
Notch/RBPJk signaling pathway inhibits 
osteoclast differentiation (34;35).  Further studies 
are required to establish the mechanism by which 
Cx37 modulates cell number and osteoclast 
differentiation through the Notch signaling 
pathway. 
The absence of Cx37 in osteoblasts does not 
appear to alter the ability of these cells to 
synthesize bone matrix. However, our preliminary 
studies show that MLO-Y4 osteocytic cells in 
which the expression of Cx37 has been silenced 
using shRNA exhibit reduced RANKL/OPG ratio 
(not shown), which could contribute to reduced 
osteoclast formation. This contrasts with the effect 
of deletion of Cx43 from osteocytic cells, which 
results in higher RANKL/OPG ratio and increased 
osteoclastic bone resorption on endocortical bone 
surfaces (20;45). Cell-specific deletion of the 
Cx37 will be required to determine whether 
changes in osteoclastogenic cytokines expressed 
by osteocytes contribute to increased bone mass in 
Cx37-/- mice.  
The phenotype of Cx37-/- mice is more 
pronounced in males than in females. Although the 
reasons for this sexual dimorphic skeletal 
phenotype are not known, the milder phenotype 
observed in female mice could be due to altered 
sex steroid levels secondary to the deficient oocyte 
maturation and abnormal corpora lutea previously 
reported (14). We confirmed the absence of 
terminally differentiated oocytes in our female 
Cx37-/- mice (Fig. 10). More osteoclasts resulting 
from lower circulating estrogens could counteract 
the decreased osteoclasts induced by Cx37 
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deficiency in female mice. Remarkably, a similar 
gender-specific effect has been recently found in a 
polymorphism of the Cx37 gene associated with 
decreased bone mass in males, but not in females 
in a Japanese population (13). This suggests that 
the presence of androgen, rather than changes in 
estrogen levels, is required for the effect of Cx37 
deletion in bone. Future work will explore the 
potential interaction between estrogen and 
androgen with Cx37. 
     Deletion of Cx37 has a more profound effect at 
2-2.5-month of age than in 5-month-old mice. This 
is evidenced by a higher bone volume and lower 
osteoclast and eroded surface in the vertebral bone 
of younger Cx37-/- animals compared to wild-type. 
Together with the fact that the difference in spinal 
BMD between the 2 genotypes is maintained 
throughout the study, this evidence suggests that 
deletion of Cx37 has a greater impact in the 
developing skeleton and is maintained into 
adulthood in the spine. The consistent response at 
the vertebra is contrasted with that at the long 
bones, where the phenotype existed across the age-
span when assessed by DEXA, but only at the 
younger aged animals when trabecular bone was 
measured using μCT.  The reason for the absence 
of effect in the distal femur (and the proximal 
tibia, not shown) at 5 months is not clear and 
warrants further investigation. 
     The higher effect of Cx37 removal on bone 
mineral density and bone volume in the cancellous 
bone and, in particular, in the axial skeleton 
contrasts with deletion of Cx43 from 
osteoblasts/osteocytes, in which the main effect is 
geometrical changes in cortical bone (20;45;46). 
Although Cx37 and Cx43 belong to the same α-
family of connexins, their channels differ 
markedly in unitary conductance, pore diameter, 
specificity of ion permeability, and, potentially, 
ability to bind intracellular molecules (47). The 
two connexins are co-expressed in several tissues, 
but with different cellular specificity, expression 
levels, and function. Thus, the connexins exert 
opposing effects on rat insulinoma cell cycle 
progression; Cx37 increases the percentage of 
cells in G0/G1 and decreases the percentage of 
cells in S-phase, whereas Cx43 decreases the 
percentage of cells in G0/G1 and increases the 
percentage in S-phase (43). In addition, Cx43, but 
not Cx37, is able to confer responsiveness to 
bisphosphonates in connexin-deficient HeLa cells 
(48). In the female reproductive tissue, Cx43 is 
expressed in granulosa cells and Cx37 is mainly 
expressed in oocytes, and the expression of both 
connexins is required for full oocyte maturation. 
Interestingly, ectopic expression of Cx43 in 
oocytes can rescue the effect of Cx37 deletion, 
suggesting that Cx43 can exert the same functions 
than Cx37 in oocytes (49). However, this is not the 
case in osteoclasts, where Cx43 is highly 
expressed but cannot compensate for the lack of 
Cx37.  
Femora from Cx37-/- mice exhibit tendencies 
towards a decrease in total bone area and towards 
an increase in marrow cavity area. Although these 
differences do not reach significance, the 
combination of these changes results in a 
significant decreased cortical thickness. Reduced 
cortical thickness could lead to lower mechanical 
strength. However, femora from Cx37-/- mice are 
stronger, as evidenced by higher ultimate force 
and stiffness. This suggests that deletion of Cx37 
results in changes in the bone matrix composition, 
likely the organic phase since it primarily dictates 
toughness while the mineral phase dictates 
modulus, leading to improved bone strength. On 
the other hand, deletion of Cx43 from mature 
osteoblasts/osteocytes or only from osteocytes 
does not change ultimate force or stiffness, but 
results in reduced bone material properties 
(Young’s modulus and ultimate stress) (50). 
Similarly, expression of a Cx43 mutant associated 
with occulodentodigital dysplasia results in 
defective material properties (51). This evidence 
suggests that Cx43 and Cx37 have different effects 
on mature osteoblasts/osteocytes synthetic activity 
or the ability of the cells to maintain the 
extracellular matrix in cortical bone. Future 
studies are required to determine the nature of the 
changes induced by Cx37 deletion on the bone 
material. 
In summary, our studies show that Cx37 
expression in osteoclast precursors is required for 
osteoclast differentiation and full maturation. Lack 
of Cx37 leads to a sustained increased in bone 
mass, in particular in the axial skeleton. Our 
findings demonstrate that Cx37 modulates 
osteoclast differentiation and therefore could be 
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targeted to reduce osteoclastic bone resorption. 
Inhibition of connexin function in vivo has been 
tested using mimetic peptides, which block 
connexin channels (52). This approach has been 
successful in preventing alterations in blood-brain 
barrier permeability and spinal cord injury (53;54), 
raising the possibility that these mimetic peptides 
could be used to target specifically osteoclast 
precursors leading to reduced bone resorption and 
maintenance of bone mass.  
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LEGENDS 
FIGURE 1. Cx37 is expressed in all bone cells, although at lower levels than Cx43. 
Cx37 and Cx43 mRNA expression measured by qPCR and corrected by GAPDH in murine lumbar 
vertebra, OB-6 and immortalized calvaria osteoblastic cells, and MLO-Y4 osteocytic cells (a); and in 
osteoblasts and osteocytes isolated from murine calvaria, and in osteoclasts obtained in vitro by treatment 
of bone marrow non-adherent cells with M-CSF and sRANKL (b). 
 
FIGURE 2. Global deletion of Cx37 increases bone mass. 
(a) Representative images of whole body histological preparations stained by alcian blue/alizarin red in 5 
day-old mice for evaluation of cartilage and calcified tissue. (b) Total body weight of male and female 
mice measured monthly from 2 to 5 months of age. Symbols correspond to mean ± SD, n=8-17. * p<0.05 
versus Cx37+/+ mice by t-test. (c) Total, spinal and femoral bone mineral density was assessed monthly by 
DEXA in Cx37+/+ and Cx37-/- mice from 2 to 5 months of age. Symbols correspond to mean ± SD, n=8-
17. * p<0.05 versus Cx37+/+ mice by t-test. 
FIGURE 3. Global deletion of Cx37 results in high bone volume in cancellous bone. µCT analysis of 
(a) cancellous bone microarchitecture in L6 vertebrae in 2.5-month-old mice (n=3-4) and L4 vertebrae in 
5-month-old mice (n=7-8); (b) cancellous bone microarchitecture in the distal femur in 2.5-month-old 
mice (n=3-4) or 5-mont-old mice (n=9-11); and (c) cortical bone geometry in the femoral midshaft in 5-
month-old mice (n=8-13). Bars are mean ± SD. * p<0.05 versus Cx37+/+ mice by t-test. Representative 
images of vertebrae from wild type and Cx37-/- littermate controls are shown in (a). 
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FIGURE 4. Mice lacking Cx37 exhibit increased mechanical strength. Biomechanical properties were 
measured in vertebral bone (n=5-8) (a) and femoral midshaft (n=8-13) (b) by compression and 3-point 
bending testing, respectively. Estimates of material properties were derived for the femoral midshaft. Bars 
are mean ± SD. * p<0.05 versus Cx37+/+ mice by t-test.  
FIGURE 5. Removal of Cx37 decreases osteoclast number in mice. Static and dynamic 
histomorphometric parameters were scored in lumbar vertebra bone sections of 2.5- (a) and 5- (b) month-
old Cx37+/+ and Cx37-/- male mice. (a and b) Osteoclast number (NOc/BS), surface covered by osteoclasts 
(OcS/BS), eroded surface (ES/BS), number of osteoblasts (NOb/BS), surface covered by osteoblasts 
(ObS/BS), quiescent surface (QS/BS), were measured in vertebral bone sections stained for TRAPase. 
Bars are mean ± SD, n=4. * p<0.05 versus Cx37+/+ mice by t-test. Representative images of vertebral 
bone stained for mineralized bone (von Kossa tetrachrome, left) and osteoclasts (right) are shown. Scale 
bars correspond to 400 μm and 100 μm for von Kossa and TRAP images, respectively. Insets in the 
TRAP images show osteoclasts at higher magnification. Scale bars correspond to 50 μm. (c) Mineralizing 
surface (MS/BS), mineral apposition rate (MAR) and bone formation rate (BFR/BS) were measure in 
unstained sections of lumbar vertebra from 5-month-old mice. Bars are mean ± SD, n=4-5.  
FIGURE 6. Circulating markers of bone formation and resorption are not altered in mice 
expressing or lacking Cx37. Circulating levels for CTX, alkaline phosphatase, osteocalcin, and 
sclerostin were measured in serum of Cx37+/+ and Cx37-/- mice at the indicated ages. Bars are mean ± SD, 
n=4-11. 
FIGURE 7. Deficient osteoclast differentiation and fusion in Cx37 knockout mice. (a) Gene 
expression in vertebral bone preparations from Cx37+/+ and Cx37-/- littermates. mRNA relative levels 
were measured by qPCR and corrected by GAPDH. Bars are mean ± SD, n=4-10 mice/genotype. (b) 
Non-adherent cells isolated from individual animals were differentiated into osteoclasts by treatment with 
M-CSF and sRANKL for 5 days. Representative images of osteoclasts stained for TRAP are shown. Bar 
represents 400μm. Osteoclast number and size, and the number of nuclei/osteoclast were scored. Bars are 
mean ± SD, n=4 mice/genotype. (c) Dot blots show Gr1 and CD11b expression in a representative 
experiment. Numbers indicate percentage of cells positive for the marker of osteoclast precursors CD11b. 
Expression levels of CD11b, CD14 and RANK mRNA were measured in non-adherent bone marrow 
cells. mRNA relative levels were measured by qPCR and corrected by GAPDH. Bars are mean ± SD, n=4 
mice/genotype. * p<0.05 versus Cx37+/+ mice by t-test. (d) Gene expression was assessed in mature 
(differentiated) osteoclasts generated by treatment of bone marrow non-adherent cells with M-
CSF/sRANKL. Genes associated with osteoclast maturation, function and fusion are shown. mRNA 
relative levels were measured by qPCR and corrected by GAPDH. Bars are mean ± SD, n=4 
mice/genotype. * p<0.05 versus Cx37+/+ mice by t-test. 
FIGURE 8. Increased Notch signaling in osteoclasts derived from Cx37-deficient bone marrow 
cells. (a) Gene expression of non-adherent cells isolated from Cx37+/+ and Cx37-/- littermates. mRNA 
relative levels were measured by qPCR and corrected by GAPDH. Bars are mean ± SD, n=3 
mice/genotype. * p<0.05 versus Cx37+/+ mice by t-test.  (b) Cell viability was determined by MTT assay. 
Bars are mean ± SD, n=3 replicas for one mouse/genotype. * p<0.05 versus Cx37+/+ mice by one-way-
ANOVA. (c) Gene expression was assessed in mature (differentiated) osteoclasts generated by treatment 
of bone marrow non-adherent cells with M-CSF/sRANKL. Genes associated with Notch signaling are 
shown. mRNA relative levels were measured by qPCR and corrected by GAPDH. Bars are mean ± SD, 
n=3 mice/genotype. * p<0.05 versus Cx37+/+ mice by t-test. (d) Expression of Notch receptors and Hey-1 
in vertebral bone from Cx37+/+ and Cx37-/- littermates. mRNA relative levels were measured by qPCR and 
corrected by GAPDH. Bars are mean ± SD, n=6-8 mice/genotype. * p<0.05 versus Cx37+/+ mice by t-test. 
FIGURE 9. Deletion of Cx37 does not alter osteoblast differentiation. (a) Adherent bone marrow cells 
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from Cx37+/+ and Cx37-/- mice were cultured in the presence of ascorbic acid/β-glycerophosphate for 14 
days. Representative images of cells stained with alizarin red, and mineralization assessed by optical 
density are shown. Relative mRNA expression of osteoblastic genes was measured by qPCR and 
corrected by GAPDH in these cultures. Bars are mean ± SD, n=4. (b) Gene expression in 6th lumbar 
vertebra from Cx37+/+ and Cx37-/- mice measured by qPCR and corrected by GAPDH. Bars are mean ± 
SD, n=4. 
Figure 10. Lack of full oocyte maturation in Cx37-/- mice. Representative images of ovarian sections 
stained with hematoxilin/eosin from Cx37+/+ and Cx37-/- mice, showing the lack of terminally 
differentiated Graafian follicles in the Cx37 null mice. Arrows point at a Graafian follicle in the Cx37+/+ 
mice ovary. Bars represent 200μm. 
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